Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185

1.

Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation.

Guba M, Graeb C, Jauch KW, Geissler EK.

Transplantation. 2004 Jun 27;77(12):1777-82. Review.

PMID:
15223891
2.

Malignancy in kidney transplant recipients.

Kapoor A.

Drugs. 2008;68 Suppl 1:11-9. Review.

PMID:
18442297
3.

Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin.

Gaumann A, Schlitt HJ, Geissler EK.

Transpl Int. 2008 Mar;21(3):207-17. Epub 2007 Dec 5. Review.

4.

New advances in antirejection therapy.

Chan M, Pearson GJ.

Curr Opin Cardiol. 2007 Mar;22(2):117-22. Review.

PMID:
17284990
5.

Sirolimus in renal transplantation.

Morath C, Arns W, Schwenger V, Mehrabi A, Fonouni H, Schmidt J, Zeier M.

Nephrol Dial Transplant. 2007 Sep;22 Suppl 8:viii61-viii65. Review.

PMID:
17890266
6.

Fifteen years of clinical studies and clinical practice in renal transplantation: reviewing outcomes with de novo use of sirolimus in combination with cyclosporine.

Kahan BD.

Transplant Proc. 2008 Dec;40(10 Suppl):S17-20. doi: 10.1016/j.transproceed.2008.10.019. Review.

PMID:
19100899
7.

Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review.

Gutierrez-Dalmau A, Campistol JM.

Drugs. 2007;67(8):1167-98. Review.

PMID:
17521218
8.

Use of sirolimus in solid organ transplantation.

Augustine JJ, Bodziak KA, Hricik DE.

Drugs. 2007;67(3):369-91. Review.

PMID:
17335296
9.

Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.

Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.

Nephrol Dial Transplant. 2005 Nov;20(11):2517-23. Epub 2005 Jun 28.

PMID:
15985508
10.

Can immunosuppressive strategies be used to reduce cancer risk in renal transplant patients?

Geissler EK.

Transplant Proc. 2010 Nov;42(9 Suppl):S32-5. doi: 10.1016/j.transproceed.2010.07.004. Review.

PMID:
21095449
11.

The impact of mTOR inhibitors on the development of malignancy.

Geissler EK.

Transplant Proc. 2008 Dec;40(10 Suppl):S32-5. doi: 10.1016/j.transproceed.2008.10.017.

PMID:
19100904
12.

[Pro and anti-neoplastic effects of immunosuppressive drug in renal transplantation].

Infante B, Stallone G, Schena A, Maiorano A, Gesualdo L, Schena FP, Grandaliano G.

G Ital Nefrol. 2006 Jul-Aug;23(4):389-95. Review. Italian.

PMID:
17063439
13.

Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients.

Kahan BD, Yakupoglu YK, Schoenberg L, Knight RJ, Katz SM, Lai D, Van Buren CT.

Transplantation. 2005 Sep 27;80(6):749-58.

PMID:
16210961
14.

Immunosuppressive therapy in older cardiac transplant patients.

Aliabadi AZ, Zuckermann AO, Grimm M.

Drugs Aging. 2007;24(11):913-32. Review.

PMID:
17953459
15.

[Current trends in renal transplant immunosuppression].

Kes P, Basić-Jukić N.

Acta Med Croatica. 2006 Jun;60(3):243-9. Review. Croatian.

PMID:
16933837
16.
18.

Proteinuria following a switch from calcineurin inhibitors to sirolimus.

Letavernier E, Pe'raldi MN, Pariente A, Morelon E, Legendre C.

Transplantation. 2005 Nov 15;80(9):1198-203.

PMID:
16314786
19.

Minimizing the risk of posttransplant malignancy.

Campistol JM.

Transplant Proc. 2008 Dec;40(10 Suppl):S40-3. doi: 10.1016/j.transproceed.2008.10.015.

PMID:
19100906
20.

Supplemental Content

Support Center